History has not been kind to PI3K inhibitors, but Scorpion Therapeutics, Inc. hopes that its mutant-selective PI3Kα inhibitor, STX-478, can do what most drugs in the class have not, which is show the high degree of efficacy that comes from targeting PI3K enzymes without the high degree of toxicity that comes with it.
Scorpion Sinks Pincers Into Funding Round For PI3K Inhibitor
The oncology-focused start-up announced it closed a $150m series C financing that it plans to use to advance STX-478.
